<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02460471</url>
  </required_header>
  <id_info>
    <org_study_id>11020</org_study_id>
    <nct_id>NCT02460471</nct_id>
  </id_info>
  <brief_title>Palliative Radiotherapy Protocol in Head and Neck Cancer</brief_title>
  <official_title>Palliative Radiotherapy for Advanced Head and Neck Carcinomas, a Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maisonneuve-Rosemont Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maisonneuve-Rosemont Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II prospective study or Palliative Radiotherapy of 25 Gy in 5 fractions, Intensity
      Modulated, for frail patients with incurable head and neck cancer. Comprehensive Quality of
      life (QLQ-C30, head and neck module, QLQ C15 PAL) and toxicity data (CTCAE v 4.0) collected.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients deemed too frail for radical treatment or incurable because of tumour extension, as
      determined by an experienced tumour board, were eligible for this study of palliative
      radiotherapy delivered by intensity modulation, 25 Gy in 5 daily fractions over one week.
      This study was conducted in two academic centers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life</measure>
    <time_frame>from radiation treatment until 24 months planned follow-up or death</time_frame>
    <description>EORTC QLQ-C30 questionnaire (QLQ-C15-PAL and H&amp;N35 modules)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity (CTCAE v 4.0 graded)</measure>
    <time_frame>from radiation treatment until 24 months planned follow-up or death</time_frame>
    <description>CTCAE v 4.0 graded toxicities</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Progression free survival</measure>
    <time_frame>from radiation treatment until 24 months planned follow-up or progression or death</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>from radiation treatment until 24 months planned follow-up or death</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Head and Neck Neoplasms</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>palliative radiation therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 Gy in 5 daily fractions</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>palliative radiation therapy</intervention_name>
    <description>thermoplastic mask immobilization. CT in treatment position. radiation dose of 25 Gy in 5 daily fractions over one week 6 MV photons by intensity modulation. Target volume is the symptomatic tumour volume with a 5 mm margin</description>
    <arm_group_label>palliative radiation therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to give an informed consent

          -  Able to complete QOL questionnaires

          -  Deemed incurable by an experienced tumour board or unwilling to receive a radical
             course of radiation therapy

          -  Presence of measurable disease

          -  Biopsy proven squamous or salivary cancer of the head and neck region

          -  Expected survival of at least 2 months.

        Exclusion Criteria:

          -  Pregnancy

          -  No previous RT to the neck and no plan to receive concomitant chemotherapy

          -  Special histology (Lymphoma, small cell cancer, metastasis from a site other than the
             head and neck region)

          -  Unavailable for follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard Fortin, MD MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maisonneuve Rosemont Hospital, University of Montreal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maisonneuve-Rosemont Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal (CHUM)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2015</study_first_posted>
  <last_update_submitted>June 1, 2015</last_update_submitted>
  <last_update_submitted_qc>June 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maisonneuve-Rosemont Hospital</investigator_affiliation>
    <investigator_full_name>Bernard Fortin MD MSc FRCPC</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>Radiotherapy</keyword>
  <keyword>Palliative Care</keyword>
  <keyword>IMRT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

